Response to sofosbuvir-containing regimens for subtype 1a versus 1b HCV infection

Regimen	Ledipasvir-sofosbuvir (TN: 12 weeks; TE: 24 weeks)^[3,4]	Sofosbuvir-velpatasvir (12 weeks)^[5]	Glecaprevir-pibrentasivr (8 or 12 weeks)^[6]
1a	TN: 99.3%	TN: 98% (95 to >99%)	8 weeks: 98% (94 to >99%)
1a	TE: 98.8%	TE: 98% (95 to >99%)	12 weeks: 99% (96 to >99%)
1b	TN: 100%	TN: 99% (95 to 100%)	8 weeks: 100%
1b	TE: 100%	TE: 99% (95 to 100%)	12 weeks: 100%

TE: treatment-experienced; TN: treatment-naïve.

References:

Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016; 64:370.
Lawitz E, Matusow G, Dejesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016; 64:360.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889.
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483.
Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373:2599.
Zeuzem S, Foster GR, Wang S, et al. Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med 2018; 378:354.

Graphic 109906 Version 3.0